Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRAFT phase II genomics-guided treatment trial in rare malignancies
2019-003192-18Phase 2Completed
- Sponsor
- German Cancer Research Center
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alectinib, atezolizumab, vemurafenib, cobimetinib, capivasertib and 3 more in Non-hematologic malignancy and cancer, sponsored by German Cancer Research Center. Primary endpoint: Disease control rate at day 110. Started Feb 2021; status: completed.
02
Drugs
alectinibatezolizumabvemurafenibcobimetinibcapivasertib
03
Conditions
Non-hematologic malignancycancer
Beyond the preview
Go deeper on 2019-003192-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003192-18.